Last updated on February 2020

Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

Brief description of study

The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.

Clinical Study Identifier: NCT03099785

Find a site near you

Start Over